“…As a consequence, v-Erb A can function as a dominant-negative inhibitor of c-Erb A function, and v-Erb A has been proposed to operate in the erythroleukemic cell by interfering with thyroid hormone signaling (Damm et al, 1989;Evans, 1989;Sap et al, 1989;Schroeder et al, 1992b;Samarut, 1996;Bauer et al, 1998;Stunnenberg et al, 1999;Thormeyer and Baniahmad, 1999;Urnov et al, 2000;Rietveld et al, 2001). However, simple dominant-negative mutants in human thyroid hormone receptors are associated with an endocrine disorder, resistance to thyroid hormone (RTH) syndrome, rather than neoplasia (Usala, 1991;Refetoff, 1993;DeGroot, 1996;Chaterjee, 1997). We therefore examined if the additional alterations sustained by v-Erb A relative to c-Erb A contribute to the oncogenic properties of the viral protein.…”